Suggested remit: To appraise the clinical and cost effectiveness of ixazomib in combination with lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma in people for whom a stem cell transplant is unsuitable.
Status In progress
Process STA 2018
ID number 1170

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
03 July 2018 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma. Following an update from the company, the timelines for this appraisal are to be confirmed whilst the company await the outcome of the next planned interim analysis of the ongoing TOURMALINE-MM2 trial being undertaken in this indication. NICE will continue to monitor development and will update interested parties as and when the situation changes.
25 April 2018 - 24 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
19 September 2016 In progress, DH referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance